Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?

Maximilian Niyazi; Patrick N. Harter; Elke Hattingen; Maya Rottler; Louisa von Baumgarten; Martin Proescholdt; Claus Belka; Kirsten Lauber; Michel Mittelbronn

doi:10.18632/oncotarget.6320

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?

Maximilian Niyazi, Patrick N. Harter, Elke Hattingen, Maya Rottler, Louisa von Baumgarten, Martin Proescholdt, Claus Belka, Kirsten Lauber _ and Michel Mittelbronn

PDF | HTML | How to cite

Oncotarget. 2016; 7:2313-2328. https://doi.org/10.18632/oncotarget.6320

Metrics: PDF 2809 views | HTML 3594 views | ?

Abstract

Maximilian Niyazi1,2, Patrick N. Harter2,3, Elke Hattingen4, Maya Rottler1,2, Louisa von Baumgarten5, Martin Proescholdt6, Claus Belka1,2, Kirsten Lauber1,2 and Michel Mittelbronn2,3

1 Department of Radiation Oncology, University of Munich, Germany

2 German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany

3 Institute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany

4 Department of Neuroradiology, University Hospital Bonn, Bonn, Germany

5 Department of Neurology, University of Munich, Munich, Germany

6 Department of Neurosurgery, University Hospital Regensburg, Regensburg, Germany

Correspondence to:

Kirsten Lauber, email:

Keywords: glioma, radiotherapy, bevacizumab, angiogenesis, VEGF

Received: August 19, 2015 Accepted: October 13, 2015 Published: November 13, 2015

Abstract

Glioblastoma (GBM) represents the most frequent primary brain tumor in adults and carries a dismal prognosis despite aggressive, multimodal treatment regimens involving maximal resection, radiochemotherapy, and maintenance chemotherapy. Histologically, GBMs are characterized by a high degree of VEGF-mediated vascular proliferation. In consequence, new targeted anti-angiogenic therapies, such as the monoclonal anti-VEGF-A antibody bevacizumab, have proven effective in attenuating tumor (neo)angiogenesis and were shown to possess therapeutic activity in several phase II trials. However, the role of bevacizumab in the context of multimodal therapy approaches appears to be rather complex. This review will give insights into current concepts, limitations, and controversies regarding the molecular mechanisms and the clinical benefits of bevacizumab treatment in combination with radio(chemo)therapy - particularly in face of the results of recent phase III trials, which failed to demonstrate convincing improvements in overall survival (OS).

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6320

Publication Alerts

Reviews:

Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?

Abstract